Comparison 2. NVP‐based vs LPV/r‐based first line antiretroviral therapy.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Treatment failure (virological failure or treatment discontinuation)	3		Hazard Ratio (Fixed, 95% CI)	1.79 [1.33, 2.41]
2 Treatment failure (virological failure or treatment discontinuation)	2		Hazard Ratio (Fixed, 95% CI)	2.01 [1.47, 2.77]
2.1 Infants (less than 12 months old)	2		Hazard Ratio (Fixed, 95% CI)	2.03 [1.24, 3.32]
2.2 Children (older than 12 months)	2		Hazard Ratio (Fixed, 95% CI)	2.00 [1.32, 3.03]
3 Virological failure or death	3		Hazard Ratio (Fixed, 95% CI)	1.84 [1.29, 2.63]
4 Virological failure or death	2		Hazard Ratio (Fixed, 95% CI)	2.28 [1.55, 3.34]
4.1 Infants (less than 12 months)	2		Hazard Ratio (Fixed, 95% CI)	3.88 [2.06, 7.30]
4.2 Children (older than 12 months)	2		Hazard Ratio (Fixed, 95% CI)	1.67 [1.03, 2.70]
5 Change in CD4% from baseline	3	356	Mean Difference (IV, Fixed, 95% CI)	1.18 [‐0.50, 2.86]
6 Change in weight z‐score from baseline	3	360	Mean Difference (IV, Random, 95% CI)	0.19 [‐0.23, 0.61]
7 Change in height z‐score from baseline	3	374	Mean Difference (IV, Fixed, 95% CI)	0.16 [‐0.01, 0.32]
8 Adverse events	3	506	Risk Ratio (M‐H, Fixed, 95% CI)	1.21 [0.88, 1.65]